Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Pirfenidone
Accession Number
DB04951
Type
Small Molecule
Groups
Approved, Investigational
Description

Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.

Structure
Thumb
Synonyms
  • pirfenidona
  • Pirfenidone
External IDs
AMR-69
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EsbrietTablet, coated801 mg/1OralGenentech, Inc.2017-01-11Not applicableUs
EsbrietCapsule267 mgOralRoche Registration Gmb H2011-02-28Not applicableEu
EsbrietTablet, coated267 mg/1OralGenentech, Inc.2017-01-11Not applicableUs
EsbrietCapsule267 mgOralRoche Registration Gmb H2011-02-28Not applicableEu
EsbrietTablet801 mgOralHoffmann La Roche2017-07-26Not applicableCanada
EsbrietCapsule267 mg/1OralGenentech, Inc.2014-10-15Not applicableUs
EsbrietTablet267 mgOralHoffmann La Roche2017-07-26Not applicableCanada
EsbrietCapsule267 mg/1OralInter Mune2014-10-16Not applicableUs
EsbrietCapsule267 mgOralHoffmann La Roche2013-01-08Not applicableCanada
EsbrietCapsule267 mgOralRoche Registration Gmb H2011-02-28Not applicableEu
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
D7NLD2JX7U
CAS number
53179-13-8
Weight
Average: 185.2218
Monoisotopic: 185.084063979
Chemical Formula
C12H11NO
InChI Key
ISWRGOKTTBVCFA-UHFFFAOYSA-N
InChI
InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
IUPAC Name
5-methyl-1-phenyl-1,2-dihydropyridin-2-one
SMILES
CC1=CN(C(=O)C=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of idiopathic pulmonary fibrosis (IPF).

Associated Conditions
Pharmacodynamics

Pirfenidone is a novel agent with anti-inflammatory, antioxidant, and antifibrotic properties. It may improve lung function and reduce the number of acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF).

Mechanism of action

Pirfenidone is an orally active, small molecule that shows a wide range of biologic activity. In vitro evidence has shown that pirfenidone inhibits collagen synthesis, down-regulates profibrotic cytokines and decreases fibroblast proliferation. Pirfenidone leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin. In addition, pirfenidone reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and furin substrate involved in carcinogenesis.

TargetActionsOrganism
UFurinNot AvailableHumans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Rapidly absorbed following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

2-2.5 hours

Clearance
Not Available
Toxicity

Generally well tolerated with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Pirfenidone.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Pirfenidone.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Pirfenidone.
8-azaguanineThe metabolism of 8-azaguanine can be decreased when combined with Pirfenidone.
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be decreased when combined with Pirfenidone.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Pirfenidone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
9-DeazaguanineThe metabolism of 9-Deazaguanine can be decreased when combined with Pirfenidone.
9-MethylguanineThe metabolism of 9-Methylguanine can be decreased when combined with Pirfenidone.
AbataceptThe metabolism of Pirfenidone can be increased when combined with Abatacept.
AbetimusThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Abetimus.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Hale ML, Margolin SB, Krakauer T, Roy CJ, Stiles BG: Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun. 2002 Jun;70(6):2989-94. [PubMed:12010989]
  2. Shi S, Wu J, Chen H, Chen H, Wu J, Zeng F: Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol. 2007 Oct;47(10):1268-76. [PubMed:17906160]
External Links
PubChem Compound
40632
PubChem Substance
175426915
ChemSpider
37115
BindingDB
50005201
ChEBI
32016
ChEMBL
CHEMBL1256391
Wikipedia
Pirfenidone
ATC Codes
L04AX05 — Pirfenidone
AHFS Codes
  • 48:02.00 — Antifibrotic Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedPreventionNeurofibromatosis Type 1 / Precancerous Conditions1
1CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)2
1RecruitingBasic ScienceImpaired kidney function1
1RecruitingTreatmentCancer, Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Metastatic Lung Cancer / Non-Squamous Non-Small Cell Neoplasm of Lung / Squamous Cell Carcinoma of Lung1
1RecruitingTreatmentGraft Versus Host Disease (GVHD) / Obliterative Bronchiolitis1
1, 2CompletedTreatmentChronic Kidney Disease (CKD) / Fibrosis1
1, 2CompletedTreatmentDiabetes Mellitus (DM) / Diabetic Nephropathies1
1, 2CompletedTreatmentDiabetic Foot Ulcers (DFU)1
2Active Not RecruitingTreatmentCardiac Failure1
2Active Not RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
2Active Not RecruitingTreatmentLung Diseases, Interstitial1
2CompletedNot AvailableIdiopathic Pulmonary Fibrosis (IPF) / Pulmonary Fibrosis1
2CompletedTreatmentAlbinism / Albinism, Oculocutaneous / Inborn Errors of Metabolism / Platelet Storage Pool Deficiency / Pulmonary Fibrosis1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Fibrosis1
2CompletedTreatmentFibrosis / Glomerulosclerosis, Focal Segmental / Nephrotic Syndrome / Proteinuria / Renal Failure1
2CompletedTreatmentHypertrophic Cardiomyopathy (HCM)1
2CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)4
2CompletedTreatmentLeiomyomas / Uterine Leiomyomas1
2CompletedTreatmentNeurofibromatosis1
2CompletedTreatmentNeurofibromatosis 1 / Plexiform Neurofibroma1
2CompletedTreatmentSclerosis, Progressive Systemic1
2CompletedTreatmentSecond-degree Burn1
2RecruitingTreatmentChronic Liver Diseases (CLD) / Fibrosis, Liver1
2RecruitingTreatmentChronic Lung Allograft Dysfunction / Disorders Related to Lung Transplantation1
2RecruitingTreatmentInterstitial Lung Disease (ILD) / Scleroderma, Systemic1
2RecruitingTreatmentLung Transplant Rejection / Restrictive Chronic Lung Allograft Dysfunction1
2RecruitingTreatmentPulmonary Fibrosis1
2RecruitingTreatmentRadiation-induced Lung Injury1
2RecruitingTreatmentRheumatoid Arthritis Interstitial Lung Disease1
2Unknown StatusTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
2Unknown StatusTreatmentRadiation Pneumonitis1
2, 3Active Not RecruitingTreatmentCLAD, Bronchiolitis Obliterans / Disorders Related to Lung Transplantation / Obliterative Bronchiolitis1
2, 3Not Yet RecruitingTreatmentSclerosis, Progressive Systemic1
2, 3RecruitingTreatmentExtrinsic Allergic Alveolitis / Pulmonary Fibrosis1
3Active Not RecruitingTreatmentAlbuminuria / Diabetic Nephropathies1
3Active Not RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3CompletedTreatmentDiabetic Foot Ulcers (DFU)1
3CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)4
3RecruitingTreatmentDermatomyositis Interstitial Lung Disease (Dm-ILD)1
3RecruitingTreatmentKeloid Scars1
3RecruitingTreatmentSystemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)1
4CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)3
4Not Yet RecruitingTreatmentAcute Kidney Injury (AKI) / Sepsis1
4Not Yet RecruitingTreatmentDermatopolymyositis / Interstitial Lung Disease (ILD)1
4Not Yet RecruitingTreatmentProgressive Idiopathic Pulmonary Fibrosis1
4RecruitingTreatmentSarcoidosis, Pulmonary1
Not AvailableActive Not RecruitingNot AvailableIdiopathic Pulmonary Fibrosis (IPF)2
Not AvailableActive Not RecruitingNot AvailablePulmonary Fibrosis1
Not AvailableApproved for MarketingNot AvailableIdiopathic Pulmonary Fibrosis (IPF)1
Not AvailableCompletedNot AvailableIdiopathic Pulmonary Fibrosis (IPF)2
Not AvailableCompletedSupportive CareRadiation Fibrosis1
Not AvailableRecruitingTreatmentInterstitial Lung Disease (ILD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral267 mg
CapsuleOral267 mg/1
TabletOral267 mg
TabletOral801 mg
Tablet, coatedOral267 mg/1
Tablet, coatedOral801 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7988994No2011-08-022026-09-22Us
US7816383No2010-10-192030-01-08Us
US8013002No2011-09-062030-01-08Us
US8084475No2011-12-272030-01-08Us
US8778947No2014-07-152033-08-30Us
US7566729No2009-07-282029-04-22Us
US7767225No2010-08-032026-09-22Us
US7635707No2009-12-222029-04-22Us
US7767700No2010-08-032027-12-18Us
US8592462No2013-11-262029-04-22Us
US8383150No2013-02-262026-09-22Us
US8318780No2012-11-272030-01-08Us
US8420674No2013-04-162027-12-18Us
US7910610No2011-03-222030-01-08Us
US8648098No2014-02-112030-01-08Us
US8754109No2014-06-172030-01-08Us
US8609701No2013-12-172029-04-22Us
US8753679No2014-06-172026-09-22Us
US7696236No2010-04-132027-12-18Us
US9561217No2017-02-072022-01-25Us
US10188637No2019-01-292037-03-28Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.89 mg/mLALOGPS
logP2ALOGPS
logP2.14ChemAxon
logS-1.8ALOGPS
pKa (Strongest Basic)-1.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity57 m3·mol-1ChemAxon
Polarizability20.28 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9932
Blood Brain Barrier+0.996
Caco-2 permeable+0.8614
P-glycoprotein substrateNon-substrate0.8193
P-glycoprotein inhibitor INon-inhibitor0.755
P-glycoprotein inhibitor IINon-inhibitor0.9177
Renal organic cation transporterNon-inhibitor0.8157
CYP450 2C9 substrateNon-substrate0.6638
CYP450 2D6 substrateNon-substrate0.8248
CYP450 3A4 substrateSubstrate0.6111
CYP450 1A2 substrateInhibitor0.9108
CYP450 2C9 inhibitorNon-inhibitor0.5982
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.7166
CYP450 3A4 inhibitorNon-inhibitor0.775
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7633
Ames testNon AMES toxic0.7652
CarcinogenicityNon-carcinogens0.8992
BiodegradationNot ready biodegradable0.9112
Rat acute toxicity2.1330 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9784
hERG inhibition (predictor II)Non-inhibitor0.6301
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-2900000000-b9809376eba9769e9bee

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridinones. These are compounds containing a pyridine ring, which bears a ketone.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Pyridinones
Alternative Parents
Methylpyridines / Dihydropyridines / Benzene and substituted derivatives / Heteroaromatic compounds / Lactams / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides
show 1 more
Substituents
Dihydropyridine / Pyridinone / Methylpyridine / Monocyclic benzene moiety / Benzenoid / Heteroaromatic compound / Lactam / Azacycle / Organic nitrogen compound / Hydrocarbon derivative
show 6 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
ring assembly, pyridone (CHEBI:32016)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Furin is likely to represent the ubiquitous endoprotease activity within constitutive secretory pathways and capable of cleavage at the RX(K/R)R consensus motif.
Gene Name
FURIN
Uniprot ID
P09958
Uniprot Name
Furin
Molecular Weight
86677.375 Da
References
  1. Burghardt I, Tritschler F, Opitz CA, Frank B, Weller M, Wick W: Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun. 2007 Mar 9;354(2):542-7. Epub 2007 Jan 10. [PubMed:17234158]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Arai T, Inoue Y, Sasaki Y, Tachibana K, Nakao K, Sugimoto C, Okuma T, Akira M, Kitaichi M, Hayashi S: Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig. 2014 Mar;52(2):136-43. doi: 10.1016/j.resinv.2013.09.002. Epub 2013 Oct 24. [PubMed:24636270]
  2. Pirfenidone FDA label [File]

Drug created on October 21, 2007 16:23 / Updated on December 08, 2019 20:10